SUMM.L Share News (SUMM)

Summit Therapeutics Swings To Annual Profit On Sarepta Agreement

LONDON (Alliance News) - Summit Therapeutics PLC on Wednesday said it swung to a profit in its most recent financial year due to the recognition of revenue from its Sarepta Therapeutics Inc pretax

Polar Capital Holds 6% Summit Therapeutics Stake After Deal (ALLISS)

LONDON (Alliance News) - Summit Therapeutics PLC said Wednesday that Polar Capital LLP holds a 6.47% stake in the drug developer after a transaction on December 21.Polar Capital's the

Summit Therapeutics proposes $25m fundraiser

(Sharecast News) - Antibiotics developer Summit Therapeutics has entered into a securities purchase agreement for the sale of $25m worth of its US-listed shares in order to extend its cash runway through to January 2020.

Summit Therapeutics' loss expands on one-off charges

(Sharecast News) - Summit Therapeutics on Tuesday reported that its third quarter loss expanded due to one-off charges, but stated that the company has swung to a profit over the first nine months of the year.

Summit Therapeutics Third-Quarter Loss Widens Due To One-Off Charges

LONDON (Alliance News) - Summit Therapeutics PLC said Tuesday its third-quarter loss widened sharply due to one-off charges.For the three months ended October 31, the company reported loss

Summit Therapeutics Discovers New Antibiotics For Superbug Infections

LONDON (Alliance News) - Clinical stage drug company Summit Therapeutics PLC on Thursday said it has discovered multiple new mechanism antibiotics to treat "superbug" antibiotics are at

Summit Therapeutics Shares Jump As Secures Extra USD12 Million Funding

LONDON (Alliance News) - Summit Therapeutics PLC on Thursday said it secured additional USD12 million from Biomedical Advanced Research & Development Authority, a division of the US Department

Summit Therapeutics Gets Encouraging Results From Ezutromid Trials

LONDON (Alliance News) - Summit Therapeutics PLC on Friday said new work showed a correlation between a reduction in a muscle damage biomarker and the use of its proposed treatment said analysis a

Summit Therapeutics Completes Dosing For PhaseOut Clinical Trial

LONDON (Alliance News) - Summit Therapeutics PLC said on Thursday it has completed the ezutromid dosing of patients with Duchenne muscular dystrophy for the full 48-week PhaseOut DMD clinical was

Tiziana Appoints Leopoldo Zambeletti As Non-Executive Director

LONDON (Alliance News) - Tiziana Life Sciences PLC, a biotechnology company developing drugs for cancer and autoimmune diseases, said Wednesday Leopoldo Zambeletti has joined

Summit Therapeutics To Raise GBP15 Million Via Share Placing (ALLISS)

LONDON (Alliance News) - Summit Therapeutics PLC said Tuesday that it intends to raise gross proceeds of up to GBP15.0 million via share placing.The to a

Summit Therapeutics Reports Progress On PhaseOut DMD Trial

LONDON (Alliance News) - Summit Therapeutics PLC at the clinical conference in Arlington highlighted the rigour in the data collection in analysis for its PhaseOut Duchenne 2

Summit Therapeutics outlines next stage of ridinilazole development

(ShareCast News) - Drug discovery and development company Summit Therapeutics outlined its Phase 3 programme for its novel antibiotic, ridinilazole, following recent regulatory meetings with the US Food and Drug Administration and European Medicines Agency. The AIM-traded firm said, with input from

Summit Therapeutics Details Phase III Programme For Ridinilazole

Summit Therapeutics Appoints David Roblin As Chief Operating Officer